Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Special Drug Use-results Surveillance for long term administration of XEPLION (Paliperidone Palmitate 1 month formulation), 25mg/ 50mg/ 75mg/ 100mg/ 150mg syringe

Trial Profile

Special Drug Use-results Surveillance for long term administration of XEPLION (Paliperidone Palmitate 1 month formulation), 25mg/ 50mg/ 75mg/ 100mg/ 150mg syringe

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK

Most Recent Events

  • 21 Apr 2020 According to Janssen media release, results from this study were published in Innovations in Clinical Neuroscience on employment status and social function improvement of schizophrenic patients treated with injection (PP1M) once a month
  • 21 Apr 2020 Results presented in a Janssen Media Release.
  • 13 Feb 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top